Drug intelligence / Profile preview

Wenjingyangxue mixture

Development stage: Unknown
Lead developer: The First Affiliated Hospital of Guangxi Medical University
Administration: Oral

Overview

Wenjingyangxue mixture is a Traditional Chinese Medicine (TCM) formulation being investigated for its clinical efficacy in treating severe intrauterine adhesions (IUA) following surgical separation (adhesiolysis). Developed and studied by The First Affiliated Hospital of Guangxi Medical University, the mixture is typically used as an adjuvant to sequential estrogen and progesterone therapy. Its proposed mechanism of action involves promoting endometrial repair and stimulating angiogenesis to improve the uterine environment and prevent the recurrence of adhesions.

Beyond the preview

Go deeper on Wenjingyangxue mixture.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Wenjingyangxue mixture.

Explore the full profile